<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753437</url>
  </required_header>
  <id_info>
    <org_study_id>Vonoprazan-1001</org_study_id>
    <secondary_id>U1111-1257-0258</secondary_id>
    <nct_id>NCT04753437</nct_id>
  </id_info>
  <brief_title>A Study of Vonoprazan in Adults With Helicobacter Pylori</brief_title>
  <official_title>A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With Vonoprazan Versus Quadruple Therapy With Esomeprazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter Pylori (H Pylori) is a bug found in the digestive system. It can cause soreness&#xD;
      and redness in the stomach (gastritis). It can also cause ulcers in the stomach and other&#xD;
      parts of the digestive system. Vonoprazan is a medicine to treat people with H Pylori. It is&#xD;
      taken together with other medicines to fight infections caused by H Pylori.&#xD;
&#xD;
      The main aim of this study is to learn if vonoprazan changes how the other medicines are&#xD;
      processed by the body. It will be compared with another medicine called esomeprazole. Other&#xD;
      aims are to check for side effects from the study medicines.&#xD;
&#xD;
      At the first visit, the study doctor will check who can take part. Participants who take part&#xD;
      will be picked for 1 of 2 treatments by chance.&#xD;
&#xD;
        -  Vonoprazan taken with bismuth, clarithromycin, and amoxicillin&#xD;
&#xD;
        -  Esomeprazole taken with bismuth, clarithromycin, and amoxicillin&#xD;
&#xD;
      Both treatments will last for 14 days. Participants will stay in the clinic throughout their&#xD;
      treatment.&#xD;
&#xD;
      After treatment, the clinic staff will telephone the participants 2 days later for a&#xD;
      check-up. The participants will visit the clinic 4 weeks later for a final check-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study in healthy participants with Helicobacter pylori (HP positive) to evaluate&#xD;
      the safety, tolerability and PK of a quadruple therapy with bismuth, clarithromycin,&#xD;
      amoxicillin, and vonoprazan versus quadruple therapy with bismuth, clarithromycin,&#xD;
      amoxicillin, and esomeprazole.&#xD;
&#xD;
      The treatment phase consists of quadruple therapy twice daily (BID) with bismuth potassium&#xD;
      citrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and vonoprazan (20 mg)&#xD;
      (Group B) or quadruple therapy BID with bismuth potassium citrate (600 mg), clarithromycin&#xD;
      (500 mg), amoxicillin (1000 mg), and esomeprazole (20 mg) (Group A) from Days 1 to 14.&#xD;
      Participants will be discharged on Day 15 after all procedures have been performed.&#xD;
&#xD;
      This single-center will be conducted in China. Participants will remain confined to the study&#xD;
      site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and&#xD;
      return on Day 42 for a follow-up assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Actual">November 5, 2021</completion_date>
  <primary_completion_date type="Actual">September 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for Bismuth</measure>
    <time_frame>Day 14: pre-morning dose and at multiple time points (up to 12 hours) post-morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time tau (τ) Over the Dosing Interval for Bismuth</measure>
    <time_frame>Day 14: pre-morning dose and at multiple time points (up to 12 hours) post-morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aeτ: Amount of Bismuth Excreted in Urine Over a Dosing Interval for Bismuth</measure>
    <time_frame>Day 14: pre-morning dose and at multiple time points (up to 12 hours) post-morning dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Experience at Least one Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Baseline up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Discontinue due to an Adverse Event (AE)</measure>
    <time_frame>Baseline up to Day 17</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>Group A: Clarithromycin + Amoxicillin + Bismuth + Esomeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, bismuth potassium citrate 600 mg, tablets, orally, twice daily, and esomeprazole 20 mg, capsules, orally, twice daily on Days 1 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Clarithromycin + Amoxicillin + Bismuth + Vonoprazan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, bismuth potassium citrate 600 mg, tablets, orally, twice daily, and vonoprazan 20 mg, tablets, orally, twice daily on Days 1 to 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Clarithromycin tablets.</description>
    <arm_group_label>Group A: Clarithromycin + Amoxicillin + Bismuth + Esomeprazole</arm_group_label>
    <arm_group_label>Group B: Clarithromycin + Amoxicillin + Bismuth + Vonoprazan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin capsules.</description>
    <arm_group_label>Group A: Clarithromycin + Amoxicillin + Bismuth + Esomeprazole</arm_group_label>
    <arm_group_label>Group B: Clarithromycin + Amoxicillin + Bismuth + Vonoprazan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth potassium citrate</intervention_name>
    <description>Bismuth potassium citrate tablets.</description>
    <arm_group_label>Group A: Clarithromycin + Amoxicillin + Bismuth + Esomeprazole</arm_group_label>
    <arm_group_label>Group B: Clarithromycin + Amoxicillin + Bismuth + Vonoprazan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Esomeprazole tablets.</description>
    <arm_group_label>Group A: Clarithromycin + Amoxicillin + Bismuth + Esomeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>Vonoprazan tablets.</description>
    <arm_group_label>Group B: Clarithromycin + Amoxicillin + Bismuth + Vonoprazan</arm_group_label>
    <other_name>TAK-438</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HP positive participants.&#xD;
&#xD;
          2. Weighs at least 50 kilogram (kg) and has a body mass index between greater than (&gt;) 18&#xD;
             and less than equal to (&lt;=) 30 kilogram per square meter (kg/m^2), inclusive, at&#xD;
             screening and Day -1 (check-in).&#xD;
&#xD;
          3. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1)&#xD;
             until the Follow-up call on Day 17.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1).&#xD;
&#xD;
          2. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol&#xD;
             abuse (defined as regular consumption of 21 units or more units per week) at any time&#xD;
             prior to the Screening Visit or is unwilling to agree to abstain from alcohol and&#xD;
             drugs throughout the study (up to Day 17).&#xD;
&#xD;
          3. Has history of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive&#xD;
             esophagitis, duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison&#xD;
             syndrome, or has current or recent (within 6 months) gastrointestinal disease that&#xD;
             would be expected to influence the absorption of drugs.&#xD;
&#xD;
          4. Has undergone therapeutic upper gastrointestinal endoscopic therapy (example,&#xD;
             endoscopic hemostasis or excision including biopsy) within 30 days prior to Screening.&#xD;
&#xD;
          5. Has undergone major surgical procedures within the past 1 month or are scheduled to&#xD;
             undergo surgical procedures that may affect gastric acid secretion (example, abdominal&#xD;
             surgery, vagotomy, or craniotomy).&#xD;
&#xD;
          6. Has a history of cancer, except basal cell carcinoma or Stage 1 squamous cell&#xD;
             carcinoma of the skin that has been in remission for at least 5 years prior to Day 1.&#xD;
&#xD;
          7. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus&#xD;
             (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen at Screening.&#xD;
&#xD;
          8. Has used nicotine-containing products (including but not limited to cigarettes, pipes,&#xD;
             cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to&#xD;
             Check-in. Cotinine test is positive at Screening or Check-in.&#xD;
&#xD;
          9. Has poor peripheral venous access.&#xD;
&#xD;
         10. Has donated or lost 450 milliliter (mL) or more of his blood volume (including&#xD;
             plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day&#xD;
             1.&#xD;
&#xD;
         11. Has abnormal Screening or Check-in laboratory values that suggest a clinically&#xD;
             significant underlying disease or subject with the following laboratory abnormalities:&#xD;
             alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin &gt;&#xD;
             the upper limit of normal (ULN).&#xD;
&#xD;
         12. Has reduced renal function assessed by having an estimated glomerular filtration rate&#xD;
             &lt;90 milliliter per min per 1.73 square meter (mL/min/1.73 m^2) (as estimated by&#xD;
             Chronic Kidney Disease-Epidemology Collaboration) at Screening or Check-in.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University, Phase I Unit</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/6036adec20847c001e116be1</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

